Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec;8(24):1707.
doi: 10.21037/atm-20-1620.

Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence

Orestis Tsonis  1 , Fani Gkrozou  2 , Konstantinos Vlachos  3 , Minas Paschopoulos  1 , Michail C Mitsis  3 , Nikolaos Zakynthinakis-Kyriakou  4 , Stergios Boussios  5   6 , George Pappas-Gogos  3
Affiliations
Review

Upfront debulking surgery for high-grade serous ovarian carcinoma: current evidence

Orestis Tsonis et al. Ann Transl Med. 2020 Dec.

Abstract

High-grade serous ovarian carcinoma (HGSOC) is a leading cause of mortality among women worldwide. Currently, there is no clear consensus over the regime these patients should receive. The main two options are upfront debulking surgery with adjuvant chemotherapy or neoadjuvant chemotherapy followed by interval debulking surgery (IDS). The former approach is proposed to be accompanied by lower chemoresistance rates but could lead to severe surgical comorbidities and lower quality of life (QoL). Optimizing patient's selection for upfront debulking surgery might offer higher progression-free and overall survival rates. Further studies need to be conducted in order to elucidate the predictive factors, which are favorable for patients undergoing upfront debulking surgery in cases of high-grade serous ovarian cancer.

Keywords: Upfront debulking surgery; chemotherapy; cytoreductive surgery; high-grade serous ovarian cancer; interval debulking surgery (IDS).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-1620). The series “Ovarian Cancer: State of the Art and Perspectives of Clinical Research” was commissioned by the editorial office without any funding or sponsorship. SB serves as an unpaid editorial board member of Annals of Translational Medicine from Nov 2019 to Oct 2021. The authors have no other conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Boussios S, Karihtala P, Moschetta M, et al. Combined strategies with Poly (ADP-Ribose) Polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review. Diagnostics (Basel) 2019;9:87. 10.3390/diagnostics9030087 - DOI - PMC - PubMed
    1. Boussios S, Karihtala P, Moschetta M, et al. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs 2020;38:181-93. 10.1007/s10637-019-00867-4 - DOI - PubMed
    1. Boussios S, Karathanasi A, Cooke D, et al. PARP inhibitors in ovarian cancer: the route to "Ithaca". Diagnostics (Basel) 2019;9:55. 10.3390/diagnostics9020055 - DOI - PMC - PubMed
    1. Cojocaru E, Parkinson CA, Brenton JD. Personalising Treatment for High-Grade Serous Ovarian Carcinoma. Clin Oncol (R Coll Radiol) 2018;30:515-24. 10.1016/j.clon.2018.05.008 - DOI - PubMed
    1. Singh N, McCluggage WG, Gilks CB. High-grade serous carcinoma of tubo-ovarian origin: recent developments. Histopathology 2017;71:339-56. 10.1111/his.13248 - DOI - PubMed